PF-06835375 is a selective, humanized CXCR5 -targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5 -positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases [1] [2].
In Vitro, PF-06835375 depletes B cells, follicular helper T cells (Tfh), and circulating Tfh-like cells that play critical roles in autoimmune processes[1].
References:
[1]. Zucchi D, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol. 2023;41(5):997-1008.
[2]. Cohen S, et al. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Res Ther. 2024 Jun 6;26(1):117.
In Vitro, PF-06835375 depletes B cells, follicular helper T cells (Tfh), and circulating Tfh-like cells that play critical roles in autoimmune processes[1].
References:
[1]. Zucchi D, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol. 2023;41(5):997-1008.
[2]. Cohen S, et al. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Res Ther. 2024 Jun 6;26(1):117.